TrialInvestigational new drugs2023

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.

Nour Abuhadra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.